Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that reinvests wisely to drive long-term success and two best left off your watchlist.
Two Stocks to Sell:
Five Below (FIVE)
Trailing 12-Month Free Cash Flow Margin: 7.3%
Often facilitating a treasure hunt shopping experience, Five Below (NASDAQ:FIVE) is an American discount retailer that sells a variety of products from mobile phone cases to candy to sports equipment for largely $5 or less.
Why Does FIVE Worry Us?
- Modest revenue base of $4.43 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
- Gross margin of 35.4% is below its competitors, leaving less money for marketing and promotions
- Underwhelming 10.4% return on capital reflects management’s difficulties in finding profitable growth opportunities, and its shrinking returns suggest its past profit sources are losing steam
Five Below’s stock price of $205.98 implies a valuation ratio of 31.5x forward P/E. Read our free research report to see why you should think twice about including FIVE in your portfolio.
Elanco (ELAN)
Trailing 12-Month Free Cash Flow Margin: 8%
Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE:ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries.
Why Are We Wary of ELAN?
- Muted 2.5% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
- Day-to-day expenses have swelled relative to revenue over the last two years as its adjusted operating margin fell by 3.5 percentage points
- Negative returns on capital show management lost money while trying to expand the business
Elanco is trading at $25.74 per share, or 26.8x forward P/E. Dive into our free research report to see why there are better opportunities than ELAN.
One Stock to Watch:
Medpace (MEDP)
Trailing 12-Month Free Cash Flow Margin: 26.9%
Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ:MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.
Why Are We Fans of MEDP?
- Core business can prosper without any help from acquisitions as its organic revenue growth averaged 15.9% over the past two years
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 31.7% exceeded its revenue gains over the last five years
- Free cash flow margin grew by 6.4 percentage points over the last five years, giving the company more chips to play with
At $421.39 per share, Medpace trades at 25.8x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.